Over the past two decades, we have studied various parathyroid hormone (PTH) 1-34 regimens, including once-daily and twice-daily injections without the concurrent conventional therapy. We recently studied PTH delivery by insulin pump, which produced normal, steady-state serum and urine calcium levels. The recent approval of PTH 1-84 represents an important milestone in the treatment of hypoparathyroidism. As PTH 1-84 and PTH 1-34 have similar pharmacokinetic (PK) and pharmacodynamic profiles, one can assume that many of the principles learned from studies of PTH 1-34 also apply to PTH 1-84 in the management of this rare disease.
PTH has indirect effects on the intestinal tract through the stimulation of 1,25(OH) 2 vitamin D production in the kidney. The calcium receptor, found in many areas of the body, partially controls calcium excretion in the kidney and PTH secretion from the parathyroid gland.
Conventional therapy consists of multiple oral doses of vitamin D analogues and calcium. Although this therapy is effective in raising serum calcium, it does not fully restore normal mineral homeostasis.
It bypasses the PTH effects on the kidney and bone and relies entirely on calcium transport across the gastrointestinal tract to normalise blood calcium. Without the renal calcium-retaining effects of PTH, conventional therapy may lead to renal insufficiency due to progressive nephrocalcinosis.
Until recently, the need for a replacement therapy for hypoparathyroidism had been largely ignored by the endocrine community. Although PTH first became available nearly a century ago, no controlled studies investigating replacement therapy took place before 1990. Ninety years ago, Collip demonstrated that bovine PTH was an effective replacement therapy in parathyroidectomised dogs. 1 In 1925, Albright treated a 14-year old boy with bovine PTH. 2 However, once vitamin D became the treatment of choice for hypoparathyroidism, Albright did not further pursue studies of PTH therapy. Investigation into PTH replacement remained inactive for the next 60 years, until 1990.
In the 1970s, the sequencing of the biologically active fragment, PTH 1-34, led to the study of its physiological effects, which revealed its dose-dependent anabolic effects on bone. The development of PTH 1-34 as an anabolic agent for osteoporosis continued through the next three decades and culminated in 2002 with the approval of teriparatide (rhPTH 1-34) (Forteo ® , Lilly, Indianapolis, US) for osteoporosis. 3 In 1990, Strogmann reported the successful treatment of two adolescents with hypoparathyroidism with PTH 1-38 injections. 4 In 1991, we initiated the first randomised controlled studies of replacement therapy with synthetic human PTH 1-34. 5 The majority of patients referred to us for therapy had evidence of renal calcifications. Some of these patients had renal insufficiency and others were in renal failure. These comorbidities were a direct result of conventional therapy or recurrent intravenous calcium infusions to treat intermittent severe hypocalcemia.
Over the past 25 years, we have evaluated various dose regimens of synthetic human PTH 1-34, including once-daily and twice-daily subcutaneous PTH 1-34 injections without the use of calcitriol or calcium supplements in adults and children of all aetiologies. The National Institutes of Health (NIH) pharmacy formulated synthetic human PTH 1-34 in single dose vials. The PTH dosage was individually titrated to achieve optimal calcium homeostasis. 6 A three-year controlled study comparing PTH to conventional therapy in both adults and children confirmed that PTH could maintain normal serum and urine calcium levels and was an effective long-term therapy. Bone density remained stable in adults and children had normal bone accrual. 7, 8 To further refine replacement therapy, we studied PTH delivery by insulin pump. A significant therapeutic breakthrough in the study of hypoparathyroidism, pump delivery produced normal, steady-state urine and serum calcium levels. PTH delivered by pump allowed for simultaneous normalisation of bone markers, serum calcium, magnesium and urine calcium excretion levels in patients of all aetiologies, including congenital hypoparathyroidism. 9, 10 We have arrived at three essential therapeutic principles that underlie successful treatment of this rare disorder.
• Individualised PTH requirements depend upon the disease aetiology.
• Smaller, more frequent doses of PTH replacement by subcutaneous injection reduce stimulation to bone and kidney and result in lower calcium excretion and markers of bone turnover. Most outcome measures are dose dependent, including blood and urine calcium levels, markers of bone turnover, bone density in adults and bone accrual in children.
• PTH delivered by pump produced the most physiological biochemical profile. (PK) studies demonstrate that they are very similar. 11, 12 Study results with fixed daily PTH 1-84 doses raise questions regarding the potential long-term effects of this approach. Sikjaer et al., showed that 100 mcg of PTH 1-84 given once daily along with conventional therapy produced hypercalcemia six to 14 hours after the injection. 12 The recent multicentre Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH ) for the Treatment of Adults with Hypoparathyroidism (REPLACE) study reported higher mean urine calcium levels in the treatment group than in the placebo group. 13 Longterm treatment studies report both anabolic 14, 15 and catabolic effects 16 
